Shire buys Pfizer’s investigational IBD biologic
Shire is buying global rights to Pfizer’s investigational biologic PF-00547659 for inflammatory bowel disease.
Read More
Tag: PF-00547659
- Cure Parkinson’s convenes expert panel to assess £2 million combination therapy funding call
- Kygevvi approved in Europe as first treatment for TK2d
- Tozorakimab shows significant benefit in two major COPD trials
- Daratumumab becomes first oncology injectable approved for patient administration
- Laigo Bio completes final close of €17m seed financing round
